Ruxolitinib compared with best available therapy for essential thrombocythaemia patients resistant or intolerant to hydroxycarbamide in majic: an investigator lead randomized trial
Egile Nagusiak: | , , , , , , , , , , , , , , , |
---|---|
Formatua: | Conference item |
Argitaratua: |
Ferrata Storti Foundation
2016
|